Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMX2084)

Drug Name
GALLOCATECHIN GALLATE Drug Info
Synonyms
(-)-Gallocatechin gallate; 4233-96-9; Gallocatechin gallate; (-)-Gallocatechol gallate; UNII-IRW3C4Y31Q; (2S,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxybenzoate; Gallocatechin gallate (Gcg); IRW3C4Y31Q; CHEMBL264938; (-)-gallocatechin-3-O-gallate; (2S,3R)-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-(3,4,5-trihydroxybenzoate); [(2S,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate; Benzoic acid, 3,4,5-trihydroxy-, 3,
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5276890
ChEBI ID
CHEBI:156284
CAS Number
CAS 5127-64-0
TTD Drug ID
DMX2084

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Approved Drug(s)
Preclinical Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Plasmodium Beta-hydroxyacyl-ACP dehydratase (Malaria FabZ)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Epigallocatechin gallate DMCGWBJ Hepatic fibrosis DB93.0 Phase 3 [1]
MORIN DM2OGZ5 Discovery agent N.A. Investigative [1]
biochanin A DM0HPWY Discovery agent N.A. Investigative [1]
3,7,3',4'-TETRAHYDROXYFLAVONE DMES906 Discovery agent N.A. Investigative [1]
(-)-CATECHINGALLATE DMZOGSK Discovery agent N.A. Investigative [1]
2-Hexadecynoic acid DMTFIPZ Discovery agent N.A. Investigative [2]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Targeting Fatty acid synthase (FASN)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cerulenin DM6N4PR Weight loss MG43.5 Approved [3]
Epigallocatechin gallate DMCGWBJ Hepatic fibrosis DB93.0 Phase 3 [1]
TVB-2640 DM19GUH Astrocytoma 2A00.0Y Phase 2 [4]
TVB-2640 DM19GUH Astrocytoma 2A00.0Y Phase 2 [5]
FAS1 DMAX2EW Fungal infection 1F29-1F2F Preclinical [6]
FSA2 DMLNRCI Fungal infection 1F29-1F2F Preclinical [6]
MORIN DM2OGZ5 Discovery agent N.A. Investigative [1]
biochanin A DM0HPWY Discovery agent N.A. Investigative [1]
3,7,3',4'-TETRAHYDROXYFLAVONE DMES906 Discovery agent N.A. Investigative [1]
(-)-CATECHINGALLATE DMZOGSK Discovery agent N.A. Investigative [1]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Plasmodium Enoyl-ACP reductase (Malaria fabI)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Triclosan DMZUR4N Malaria 1F40-1F45 Approved [7]
Epigallocatechin gallate DMCGWBJ Hepatic fibrosis DB93.0 Phase 3 [8]
Nicotinamide-Adenine-Dinucleotide DM9LRKB N. A. N. A. Investigative [9]
Beta-D-Glucose DM5IHYP Discovery agent N.A. Investigative [9]
MORIN DM2OGZ5 Discovery agent N.A. Investigative [1]
3,7,3',4'-TETRAHYDROXYFLAVONE DMES906 Discovery agent N.A. Investigative [1]
(-)-CATECHINGALLATE DMZOGSK Discovery agent N.A. Investigative [1]
Thiolactomycin DMBAWDG Malaria 1F40-1F45 Investigative [7]
Diazaborines DM5UFZX Discovery agent N.A. Investigative [10]
ISORHAMNETIN DMQ4Z6E Discovery agent N.A. Investigative [1]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Epigallocatechin gallate DMCGWBJ Hepatic fibrosis DB93.0 Phase 3 [1]
Chrysin DM7V2LG Discovery agent N.A. Investigative [1]
KAEMPFEROL DMHEMUB Discovery agent N.A. Investigative [1]
MORIN DM2OGZ5 Discovery agent N.A. Investigative [1]
3,7,3',4'-TETRAHYDROXYFLAVONE DMES906 Discovery agent N.A. Investigative [1]
(-)-CATECHINGALLATE DMZOGSK Discovery agent N.A. Investigative [1]
2-Hexadecynoic acid DMTFIPZ Discovery agent N.A. Investigative [2]
ISORHAMNETIN DMQ4Z6E Discovery agent N.A. Investigative [1]
NADPH DM75Q34 Discovery agent N.A. Investigative [11]
⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fatty acid synthase (FASN) TT7AOUD FAS_HUMAN Inhibitor [1]
Plasmodium Beta-hydroxyacyl-ACP dehydratase (Malaria FabZ) TTHPFTS Q965D7_PLAFA Inhibitor [1]
Plasmodium Enoyl-ACP reductase (Malaria fabI) TTNX2CS Q965D5_PLAFA Inhibitor [1]
Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG) TTBE4IR Q965D6_PLAFA Inhibitor [1]

References

1 Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
2 2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections. Bioorg Med Chem. 2010 Nov 1;18(21):7475-85.
3 Inhibition of fatty acid biosynthesis prevents adipocyte lipotoxicity on human osteoblasts in vitro. J Cell Mol Med. 2010 Apr;14(4):982-91.
4 Imidazopyridine-Based Fatty Acid Synthase Inhibitors That Show Anti-HCV Activity and in Vivo Target Modulation. ACS Med Chem Lett. 2013 January 10; 4(1): 113-117.
5 Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities. Hepatology. 2020 Jul;72(1):103-118.
6 Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22.
7 Novel molecular targets for antimalarial drug development. Chem Biol Drug Des. 2008 Apr;71(4):287-97.
8 Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR). J Med Chem. 2007 Feb 22;50(4):765-75.
9 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
10 Lipid biosynthesis as a target for antibacterial agents. Prog Lipid Res. 2001 Nov;40(6):467-97.
11 Functional characterization of beta-ketoacyl-ACP reductase (FabG) from Plasmodium falciparum. Biochem Biophys Res Commun. 2003 Mar 28;303(1):387-92.